Invivyd Files Routine 8-K for Other Events & Exhibits
Ticker: IVVD · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance, 8-K
TL;DR
**Invivyd filed a routine 8-K, no major news, just standard compliance.**
AI Summary
Invivyd, Inc. filed an 8-K on January 3, 2024, to report "Other Events" and "Financial Statements and Exhibits." This filing, under SEC File Number 001-40703, indicates standard reporting for the company, which is based in Waltham, MA, and trades on The Nasdaq Stock Market LLC under the symbol IVVD. For investors, this matters because it's a routine compliance filing, signaling that the company is adhering to its regulatory obligations, which is a positive sign for operational stability and transparency.
Why It Matters
This filing is a standard regulatory update, indicating Invivyd, Inc. is maintaining compliance with SEC requirements. It doesn't contain new material financial or operational news, but rather confirms ongoing adherence to reporting obligations.
Risk Assessment
Risk Level: low — This 8-K is a routine filing for 'Other Events' and 'Financial Statements and Exhibits' and does not disclose any new material risks or changes to the company's operations or financial health.
Analyst Insight
This filing is routine and does not provide new information to warrant immediate action. Investors should continue to monitor for more substantive filings or news releases from Invivyd, Inc. regarding their operations or financial performance.
Key Numbers
- 001-40703 — SEC File Number (identifies the company's registration with the SEC)
- 2024-01-03 — Date of Report (indicates when the earliest event reported occurred and the filing date)
- $0.0001 — par value per share (par value of Invivyd's common stock)
- 1601 Trapelo Road, Suite 178 — Business Address (Invivyd's principal executive offices)
- (781) 819-0080 — Registrant's telephone number (contact information for Invivyd, Inc.)
Key Players & Entities
- Invivyd, Inc. (company) — the registrant filing the 8-K
- 001-40703 (dollar_amount) — SEC File Number
- January 3, 2024 (date) — date of earliest event reported and filing date
- Waltham, MA (location) — address of principal executive offices
- IVVD (ticker) — trading symbol on Nasdaq
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Invivyd, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 3, 2024.
On which exchange is Invivyd, Inc.'s common stock registered and what is its trading symbol?
Invivyd, Inc.'s common stock is registered on The Nasdaq Stock Market LLC and its trading symbol is IVVD.
What is the par value per share of Invivyd, Inc.'s common stock?
The par value per share of Invivyd, Inc.'s common stock is $0.0001.
What is the business address of Invivyd, Inc. as stated in the filing?
The business address of Invivyd, Inc. is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-01-03 07:06:58
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- d277393d8k.htm (8-K) — 25KB
- d277393dex991.htm (EX-99.1) — 22KB
- g277393g0103035319803.jpg (GRAPHIC) — 3KB
- 0001193125-24-001013.txt ( ) — 182KB
- ivvd-20240103.xsd (EX-101.SCH) — 3KB
- ivvd-20240103_lab.xml (EX-101.LAB) — 18KB
- ivvd-20240103_pre.xml (EX-101.PRE) — 11KB
- d277393d8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events. On January 3, 2024, Invivyd, Inc. issued a press release entitled "Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: January 3, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary